Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Declines By 71.0%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 19,200 shares, a decline of 71.0% from the September 15th total of 66,300 shares. Based on an average trading volume of 229,900 shares, the days-to-cover ratio is currently 0.1 days.

TC Biopharm Stock Down 0.2 %

NASDAQ TCBP traded down $0.01 during mid-day trading on Friday, reaching $5.12. 127,046 shares of the stock were exchanged, compared to its average volume of 256,076. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.88 and a current ratio of 0.88. The business’s 50 day moving average is $5.34 and its 200-day moving average is $9.27. TC Biopharm has a 1 year low of $2.11 and a 1 year high of $138.00.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.